Advertisement

Trends in mammography, hormone replacement therapy, and breast cancer incidence and mortality in Canadian women

  • D. Zakaria
  • A. Shaw
Original Paper
  • 11 Downloads

Abstract

Purpose

The purpose of the study is to examine relationships between long-term trends of region- and age-specific rates of mammography, hormone replacement therapy (HRT), and breast cancer incidence and mortality in Canadian women aged 35 years and older.

Methods

Population-based complex surveys were used to estimate mammography use in the past 2 years and ever, and HRT use in the past month. National population-based administrative data were used to estimate breast cancer incidence and mortality. Joinpoint analyses were used to estimate trends in rates and years where trend changed.

Results

No consistent relationship between mammography use and breast cancer incidence was observed across age groups. Opportunistic screening occurred prior to the establishment of organized screening programs in Canada and prior to substantial declines in breast cancer mortality observed around 1990. Women aged 35–39 years demonstrated a 62.8% relative decrease in breast cancer mortality between 1950 and 2015 despite lower rates of mammography use in the past 2 years (range 9.4–15.9%) reinforcing important treatment advances. A substantial proportion of women in their 40s report mammography use in the past 2 years (range 35.8–42.2%) and regional variation exists reflecting inconsistencies in guidelines across Canada.

Conclusion

Rates of mammography use over time do not necessarily reflect national guideline releases or establishment of organized screening programs.

Keywords

Mammography Hormone replacement therapy Breast cancer Incidence Mortality 

Notes

Author contributions

Both authors contributed to study design, interpretation of results, drafting the manuscript, critical revisions, and approval of the final manuscript. D.Z. performed the analyses.

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.

References

  1. 1.
    Canadian Cancer Society’s Advisory Committee on Cancer Statistics (2017) Canadian cancer statistics 2017. Canadian Cancer Society, Toronto (ON). http://cancer.ca/Canadian-Cancer-Statistics-2017-EN. Accessed 11 July 2017
  2. 2.
    Canadian Task Force on the Periodic Health Examination (1979) The periodic health examination. CMAJ 121:1193–1254Google Scholar
  3. 3.
    Canadian Task Force on the Periodic Health Examination (1986) The periodic health examination: 2. 1985 update. Can Med Assoc J 134:724–729Google Scholar
  4. 4.
    Canadian Task Force on the Periodic Health Examination (1994) The Canadian guide to clinical preventive health care. Canada Communication Group—Publishing, OttawaGoogle Scholar
  5. 5.
    Ringash J, with the Canadian Task Force on Preventive Health Care (2001) Preventive health care, 2001 update: screening mammography among women aged 40–49 years at average risk of breast cancer. CMAJ 164(4):469–476PubMedPubMedCentralGoogle Scholar
  6. 6.
    Canadian Task Force on Preventive Health Care (2011) Recommendations on screening for breast cancer in average risk women aged 40–74. CMAJ 183(17):1991–2001CrossRefGoogle Scholar
  7. 7.
    Canadian Partnership Against Cancer (2016) Breast cancer screening in Canada: monitoring and evaluation of quality indicators—Results Report, January 2011 to December 2012. Canadian Partnership Against Cancer, Toronto. https://content.cancerview.ca/download/cv/prevention_and_screening/screening_and_early_diagnosis/documents/breast_cancer_screening_canada_monitoring_evaluating_report_2011_12p?attachment=0. Accessed 8 April 2018
  8. 8.
    Harding C, Pompei F, Burmistrov D, Welch G, Abebe R, Wilson R (2015) Breast cancer screening, incidence, and mortality across US counties. JAMA Intern Med 175(9):1483–1489CrossRefGoogle Scholar
  9. 9.
    Gompel A, Plu-Bureau G (2010) Is the decrease in breast cancer incidence related to a decrease in postmenopausal hormone therapy? Ann N Y Acad Sci 1205:268–276CrossRefGoogle Scholar
  10. 10.
    De P, Neutel CI, Olivotto I, Morrison H (2010) Breast cancer incidence and hormone replacement therapy in Canada. J Natl Cancer Inst 102:1489–1495CrossRefGoogle Scholar
  11. 11.
    Ravdin PM, Cronin KA, Howlader N et al (2007) The decrease in breast cancer incidence in 2003 in the United States. N Engl J Med 356:1670–1674CrossRefGoogle Scholar
  12. 12.
    Glass AG, Lacey JV, Carreon JD, Hoover RN (2007) Breast cancer incidence, 1980–2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. JNCI 99(15):1152–1161CrossRefGoogle Scholar
  13. 13.
    Morrell S, Taylor R, Roder D, Robson B, Gregory M, Craig K (2017) Mammography service screening and breast cancer mortality in New Zealand: a national cohort study 1999–2011. BJC 116:828–839CrossRefGoogle Scholar
  14. 14.
    Welch HG, Prorok PC, O’Malley AJ, Kramer BS (2016) Breast-cancer tumor size, overdiagnosis, and mammography screening effectiveness. N Engl J Med 375(15):1438–1447CrossRefGoogle Scholar
  15. 15.
    Bleyer A, Baines C, Miller AB (2016) Impact of screening mammography on breast cancer mortality. Int J Cancer 138(8):2003–2012CrossRefGoogle Scholar
  16. 16.
    Narod SA, Iqbal J, Miller AB (2015) Why have breast cancer mortality rates declined? J Cancer Policy 5:8–17CrossRefGoogle Scholar
  17. 17.
    Coldman A, Phillips N, Wilson C, Decker K, Chiarelli AM, Brisson J, Zhang B, Payne J, Doyle G, Ahmad R (2015) Pan-Canadian study of mammography screening and mortality from breast cancer. J Natl Cancer Inst 106(11).  https://doi.org/10.1093/jnci/dju261
  18. 18.
    Gotzsche PC, Jorgensen KJ (2013) Screening for breast cancer with mammography. Cochrane Database Syst Rev 6:CD001877Google Scholar
  19. 19.
    Autier P, Koechlin A, Smans M, Vatten L, Boniol M (2012) Mammography screening and breast cancer mortality in Sweden. J Natl Cancer Inst 104:1080–1093CrossRefGoogle Scholar
  20. 20.
    Shields M, Wilkins K (2009) An update on mammography use in Canada. Health Rep 20:7–19PubMedGoogle Scholar
  21. 21.
    International Rules for Multiple Primary Cancers (ICD-O Third Edition) (2004) Internal Report No. 2004/02. IARC, Lyon. http://www.iacr.com.fr/images/doc/MPrules_july2004.pdf. Accessed 1 June 2017
  22. 22.
    World Health Organization (1977) International classification of diseases, ninth revision. World Health Organization, GenevaGoogle Scholar
  23. 23.
    International Classification of Diseases for Oncology, 3rd edition, 1st revision (ICD-O-3.1) (2017). International Agency for Research on Cancer, Lyon, France. http://codes.iarc.fr/abouticdo.php. Accessed 16 Feb 2017
  24. 24.
    World Health Organization (1992) International statistical classification of diseases and related health problems, Tenth Revision. World Health Organization, GenevaGoogle Scholar
  25. 25.
    Statistics Canada. CANSIM database: Table 051-0001: Estimates of population, by age group and sex for July 1, Canada, provinces and territories, released September 27, 2017. http://www5.statcan.gc.ca/cansim/a26?lang=eng&retrLang=eng&id=0510001&&pattern=&stByVal=1&p1=1&p2=-1&tabMode=dataTable&csid=. Accessed 6 October 2017
  26. 26.
    Jensen OM, Parkin DM, MacLennan R, Muir CS, Skeet RG (eds) (1991) Cancer registration: principles and methods. International Agency for Research on Cancer, Lyon, FranceGoogle Scholar
  27. 27.
    Kim HJ, Fay MP, Feuer EJ, Midthune DN (2000) Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 19:335–351 correction:2001;20:655CrossRefGoogle Scholar
  28. 28.
    Joinpoint Regression Program, version 4.2.0.2—June 2015; Statistical Methodology and Applications Branch, Surveillance Research Program, National Cancer InstituteGoogle Scholar
  29. 29.
    Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333CrossRefGoogle Scholar
  30. 30.
    Sprague BL, Trentham-Dietz A, Cronin KA (2012) A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999–2010. Obstet Gynecol 120(3):595–603CrossRefGoogle Scholar
  31. 31.
    Jemal A, Ward E, Thun MJ (2007) Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 9(3):R28CrossRefGoogle Scholar
  32. 32.
    International Agency for Research on Cancer (IARC) (2016) Breast cancer screening, vol 15. IARC Handbooks of Cancer Prevention. IARC, Lyon, FranceGoogle Scholar
  33. 33.
    Report from the Evaluation Indicators Working Group (2013) Guidelines for monitoring breast cancer screening program performance, 3rd edn. Canadian Partnership Against Cancer, TorontoGoogle Scholar
  34. 34.
    Jørgensen KJ, Kalager M, Barratt A, Baines C, Zahl PH, Brodersen J, Harris RP (2017) Overview of guidelines on breast screening: why recommendations differ and what to do about it. Breast 31:261–269CrossRefGoogle Scholar
  35. 35.
    Goodman MT, Nomura AM, Wilkens LR, Kolonel LN (1990) Agreement between interview information and physician records on history of menopausal estrogen use. Am J Epidemiol 131(5):815–825CrossRefGoogle Scholar
  36. 36.
    Doyle GP, Major D, Chu C, Stankiewicz A, Harrison ML, Pogany L, Mai VM, Onysko J (2011) A review of screening mammography participation and utilization in Canada. Chronic Dis Inj Can 31(4):152–156PubMedGoogle Scholar
  37. 37.
    National Center for Health Statistics (2017) Health, United States, 2016: With Chartbook on Long-term Trends in Health. National Center for Health Statistics, HyattsvilleGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Centre for Surveillance and Applied Research, Health Promotion and Chronic Disease Prevention BranchPublic Health Agency of CanadaOttawaCanada

Personalised recommendations